Morphocell’s expanded Series A funding strengthens its plans to advance engineered liver tissue therapies and scale globally.
Morphocell Technologies Inc, a Canadian biotech working to create next-generation tissue therapeutics for organ replacement, has closed its Series A financing at US$50 million, following a new US$10 million extension led by Investissement Québec and CDP Venture Capital [1].
The add-on builds on a US$40 million round completed in early 2024 and gives the company more than three years of operational runway, significant for a regenerative-medicine startup advancing complex, cell-based therapies.
For Morphocell, the latest investment signals not only financial backing but international validation.
“Since our initial Series A close, Morphocell has delivered remarkable progress across development, manufacturing and team expansion,” said CEO and co-founder Dr Massimiliano Paganelli. He called the renewed commitments “a powerful vote of confidence” in the company’s long-term potential.
Institutional participation from Investissement Québec and CDP Venture Capital brings strategic advantages. Both investors have global mandates and track records of supporting high-impact scientific ventures. Their involvement signals that engineered tissue therapeutics, once considered niche, are rapidly becoming a mainstream investment category.
The company now operates with 44 employees across Montréal, Cambridge in Boston and Toronto, running fully integrated operations from cell discovery to manufacturing. In an industry where companies often outsource large chunks of development, Morphocell’s vertical structure gives it speed, control and long-term cost efficiency.
Canadian financing corporation Investissement Québec doubled down after initially backing the company in 2024.
“The growing life-sciences industry is providing a global showcase for Québec talent and expertise,” said Investissement Québec President and CEO Bicha Ngo. “Investissement Québec is delighted to help Morphocell achieve its ambitions.”
Meanwhile, Italian venture capital firm CDP Venture Capital enters its first Canadian biotech investment.
“We are particularly proud to be part of Morphocell’s journey,” said CDP Venture Capital’s Chief Direct Investments Alessandro Scortecci. “Our investment enables the establishment of Morphocell’s first European subsidiary, in Italy,” which he notes will tap into the country’s scientific talent and industrial excellence.
Morphocell’s core platform uses induced pluripotent stem cells (iPSCs) to generate engineered tissues that replace failing organs. Its lead program, ReLiver, aims to function as a biological substitute for the liver, a lifeline for patients waiting on organ transplantation or living with chronic liver disease [2].
The challenge can be visualized this way: instead of repairing a damaged engine, Morphocell is attempting to build a mini-engine from scratch, using living cells and then integrating it into a human body. It’s a moonshot scientifically, but also one of the few technological approaches capable of scaling beyond the limitations of donor organs.
With liver disease affecting millions globally and transplants limited by donor shortages, investors are betting that engineered tissues could reshape the entire treatment landscape.
Beyond ReLiver, Morphocell plans to expand its manufacturing capabilities, grow its scientific teams and strengthen international partnerships. The newly established Italian subsidiary will serve as a European hub, supporting clinical expansion and collaboration with universities and biotech institutions.
“Morphocell’s goal has always been clear, to create revolutionary cell-based organ replacement therapies that cure patients,” Paganelli said. The financing, he added, reinforces a shared conviction that regenerative medicine can and should be built in Québec.
Government support adds further momentum. “We want to help stimulate innovation in Quebec, which will play a decisive role in the evolution of modern medicine,” said Christine Fréchette, Canadian Minister of Economy, Innovation and Energy. She emphasized the province’s growing ecosystem for high-impact biomedical innovation.
With US$50 million in secured funding, Morphocell ranks among Canada’s most well-funded private regenerative medicine companies. The company’s scientific strategy – combining stem cell biology, tissue engineering and in-house manufacturing – positions it at the forefront of a sector racing to build functional alternatives to failing organs.
Morphocell’s secured funding is a signal that regenerative medicine is crossing a threshold where bold scientific ambition finally meets institutional confidence. Engineered organ replacements remain one of the most technically demanding challenges in biotech, but they’re also among the few solutions capable of rewriting how modern healthcare confronts organ failure.
If Morphocell delivers, the real disruption won’t just be technological; it will reshape who gets access to life-saving care and how quickly those benefits can scale beyond the operating room.
[1] https://www.morphocell.com/updates/completion-of-50m-series-a
[2] https://www.morphocell.com/products
